Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo

Anticancer Research

Volumn 19, Issue 5 B, 1999, Pages 3809-3816

  Della Porta, Paola ^a,b   Soeltl, Rita ^a   Krell, Hans Willi ^c   Collins, Kevin ^b   O'Donoghue, Maurice ^b   Schmitt, Manfred ^a   Krüger, Achim ^a,d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Aprotinin; Batimastat; Matrix metalloproteinase; Protease inhibitor; Serine protease; Tumor cell invasion

Indexed keywords

APROTININ; BATIMASTAT; CASEIN; COLLAGEN; COLLAGEN TYPE 4; MATRIX METALLOPROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER INVASION; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ADENOCARCINOMA; ANIMALS; APROTININ; COLLAGEN; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; PHENYLALANINE; PLASMINOGEN; PLASMINOGEN ACTIVATORS; PROTEASE INHIBITORS; SERINE PROTEINASE INHIBITORS; THIOPHENES; TUMOR CELLS, CULTURED;

EID: 0032763013     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Liotta LA, Kleinerman J, Catanzaro P, Rynbrandt D: Degradation of basement membrane by murine tumor cells. J Natl Cancer Inst 58: 1427-1431, 1977.
2. Tryggvason K, Hoyhtya M, Salo T: Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 907: 191-217, 1987.
3. Stetler-Stevenson WG, Liotta LA, Kleiner DE: Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 7: 1434-1441, 1993.
4. Schmitt M, Wilhelm O, Janicke F, Magdolen V, Reuning U, Ohi H, Moniwa N, Kobayashi H, Weidle U, Graeff H: Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis. J Obstet Gynaecol 21: 151-165, 1995.
5. Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, Roder JD, Fink U, Siewert JR: Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 54: 2900-2907, 1994.
6. Ganesh S, Sier CF, Griffioen G, Vloedgraven HJ, de Boer A, Welvaart K, van der Velde CJ, van Krieken JH, Verheijen JH, Lamers CB, Verspaget HW: 20 Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 54: 4065-4071, 1994.
7. Nekarda H, Schlegel P, Schmitt M, Stark M, Mueller JD, Fink U, Siewert JR: Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus. Clin Cancer Res 4: 1755-1763, 1998.
8. Brown PD: Matrix metalloproteinase inhibitors: a novel class of anticancer agents. Adv Enzyme Regul 35: 293-301, 1995.
9. Parsons SL, Watson SA, Steele RJ: Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur J Surg Oncol 23: 526-531, 1997.
10. Nemunaitis J, Poole C, Primrose J, Rosemurgy A, Malfetano J, Brown P, Berrington A, Cornish A, Lynch K, Rasmussen H, Kerr D, Cox D, Millar A: Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 4: 1101-1109, 1998.
11. Brown PD: Matrix metalloproteinase inhibitors in the treatment of cancer. Med Oncol 14: 1-10, 1997.
12. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR: A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 53: 2087-91, 1993.
13. Taraboletti G, Garofalo A, Belotti D, Drudis T, Borsotti P, Scanziani E, Brown PD, Giavazzi R: Inhibition of angiogenesis and murine hemangioma growth by Batimastat, a synthetic inhibitor of matrix metalloproteinases. J Nat Cancer Inst 87: 293-298, 1995.
14. Eccles SA, Box GM, Court WJ, Bone EA, Thomas W, Brown PD: Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 56: 2815-2822, 1996.
15. Latner AL, Longstaff E, Turner GA: Anti-tumour activity 'of aprotinin. Br J Cancer 30: 60-67, 1974.
16. Guthrie D, Ross WM, Latner AL, Turner GA, Way S: Effective treatment of a patient with an advanced carcinoma of the cervix with a combination of bromocriptine and aprotinin. Br J Clin Pract 35: 330-332, 1981.
17. Utsuji S, Yamamura M, Takai S, Hioki K, Yamamoto M: Effect of aprotinin on metastasis of Lewis lung tumor in mice. Surg Today 22: 439-442, 1992.
18. DeClerck YA, Laug WE: Cooperation between matrix metalloproteinases and the plasminogen activator-plasmin system in tumor progression. Enzyme Protein 49: 72-84, 1996.
19. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S: Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 41: 4629-4636, 1981.
20. Mignatti P, Robbins E, Rifkin DB: Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell 47: 487-498, 1986.
21. Reith A, Rucklidge GJ: Invasion of brain tissue by primary glioma: evidence fo the involvement of urokinase-type plasminogen activator as an activator of type IV collagenase. Biochem Biophys Res Commun 186: 348-354, 1992.
22. Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Garbisa S, Mignatti P: Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J 16: 2319-2332, 1997.
23. Salo T, Liotta LA, Keski-Oja J, Turpeenniemi-Hujanen T, Tryggvason K: Secretion of basement membrane collagen degrading enzyme and plasminogen activator by transformed cells-role in metastasis. Int J Cancer 30: 669-673, 1982.
24. Azuma M, Tamatani T, Fukui K, Yoshida H, Kamogashira T, Ogino K, Suzuki T, Sato M: Role of plasminogen activators, metalloproteinases and the tissue inhibitor of metalloproteinase-1 in the metastatic process of human salivary- gland adenocarcinoma cells. Int J Cancer 54: 669-676, 1993.
25. Shah V, Kumar S, Zirvi KA: Metastasis of human colon tumor cells in vivo: correlation with the overexpression of plasminogen activators and 72 kDa gelatinase. In Vivo 8: 321-326, 1994.
26. Varani J, Burmeister B, Sitrin RG, Shollenherger SB, Inman DR, Fligiel SE, Gibbs DF, Johnson K: Expression of serine proteinases and metalloproteinases in organ-cultured human skin. Altered levels in the presence of retinoic acid and possible relationship to retinoid-induced loss of epidermal cohesion. Am J Pathol 145: 561-573, 1994.
27. Birkedal-Hansen H, Cobb CM, Taylor RE, Fullmer HM: Activation of fibroblast procollagenase by mast cell proteases. Biochim Biophys Acta 438: 273-286, 1976.
28. Nielsen BS, Timshel S, Kjeldsen L, Sehested M, Pyke C, Borregaard N, Dano K: 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer 65: 57-62, 1996.
29. Teale DM, Rees RC, Thorgeirsson UP, Liotta LA: Type IV collagenase activity of a primary HSV-2-induced hamster fibrosarcoma and its in vivo metastases and in vitro clones. Cancer 60: 1263-1268, 1987.
30. Zucker S, Lysik RM, Malik M, Bauer BA, Caamano J, Klein-Szanto AJ: Secretion of gelatinases and tissue inhibitors of metalloproteinases by human lung cancer cell lines and revertant cell lines: not an invariant correlation with metastasis. Int J Cancer 52: 366-371, 1992.
31. Ossowski L: Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor, and interstitial collagenase. Cancer Res 52: 6754-6760, 1992.
32. Krüger A, Fata JE, Khokha R: Altered tumor growth and metastasis of a T-cell lymphoma in Timp-1 transgenic mice. Blood 90: 1993-2000, 1997.
33. Krüger A, Sanchez-Sweatman OH, Martin DC, Fata JE, Ho AT, Orr FW, Ruther U, Khokha R: Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line. Oncogene 16: 2419-2423, 1998.
34. Collins JK, O'Mahony A, O'Brien F, Corbett A, Morissey D, O'Donoghue M, O'Sullivan G: Evaluation of newly established cell lines as models to study growth, invasion and metastatic spread in oesophageal cancer. Fibrinolysis Suppl 4: 83-88, 1992.
35. Fridman R, Sweeney TM, Zain M, Martin GR, Kleinman HK: Malignant transformation of NIH-3T3 cells after subcutaneous co-injection with a reconstituted basement membrane (matrigel). Int J Cancer 51: 740-744, 1992.
36. Heussen C, Dowdle EB: Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 102: 196-202, 1980.
37. Robbins KL Summaria L: Human plasminogen and plasmin. Methods Enzymol 19: 184-199, 1970.
38. Isseroff RR, Rifkin DB: Plasminogen is present in the basal layer of the epidermis. J Invest Dermatol 80: 297-299, 1983.
39. Stonelake PS, Jones CE, Neoptolemos JP, Baker PR: Proteinase inhibitors reduce basement membrane degradation by human breast cancer cell lines. Br J Cancer 75: 951-959, 1997.
40. Ikeda T, Murakami K, Hayakawa Y, Fujii H, Ohkoshi M, Saiki I: Anti-invasive activity of synthetic serine protease inhibitors and its combined effect with a matrix metalloproteinase inhibitor. Anticancer Res 18: 4259-4266, 1998.
41. Mackay AR, Corhitt RH, Hartzler JL, ThorcJeirsson UP: Basement membrane type IV collagen degradation: evidence for the involvement of a proteolytic cascade independent of metalloproteinases. Cancer Res 50: 5997-6001, 1990.
42. Pilat MJ, Lehr JE, Quigley MM, Pienta, KJ: The effect of amiloride on the metastatic properties of prostate cancer in the Dunning rat model. Oncol Rep 5: 889-892, 1998.
43. Eitzman DT, Krauss JC, Shen T, Cui J, Ginsburg D: Lack of plasminogen activator inhibitor- 1 effect in a transgenic mouse model of metastatic melanoma. Blood 87: 4718-4722, 1996.
44. Giavazzi R, Garofalo A, Ferri C, Lucchini V, Bone EA, Chiari S, Brown PD, Nicoletti MI, Taraboletti G: Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentlates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res 4: 985-992, 1998.
45. Sledge GW, Qulali M, Goulet R, Bone EA, Fife R: Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 87: 1546-1550, 1995.
46. Zbytniewski Z, Drewa G, Kanclerz A: The effect of trasylol (Trascolan "Polfa") and p-aminomethylbenzoic acid (Pamba "Germed") on the experimental metastases of transplantable melanotic melanoma in golden hamster. Arch Geschwulstforsch. 47: 400-404, 1977.
47. Lage A, Diaz JW, Gonzalez I: Effect of proteinase inhibitor in experimental tumors. Neoplasma 25: 257-259, 1978.
48. Chirivi RG, Garofalo A, Crimmin MJ, Bawden LJ, Stoppacciaro A, Brown PD, Giavazzi R: Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 58: 460-464, 1994.
49. Wilhelm O, Schmitt M, Hohl S, Senekowitsch R, Graeff H: Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin Exp Metastasis 13: 296-302, 1995.
50. Kobayashi H, Gotoh J, Shinohara H, Moniwa N, Terao T: Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type 28 plasminogen activator in the experimental and spontaneous metastasis model. Thromb Haemost 71: 474-480, 1994.
51. Min HY, Doyle LV, Vitt CR, Zandonella CL, Stratton-Thomas JR, Shuman MA, Rosenberg S: Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 56: 2428-2433, 1996.
52. DeClerck YA, Imren S, Montgomery AM, Mueller BM, Reisfeld RA, Laug WE: Proteases and protease inhibitors in tumor progression. Adv Exp Med Biol 425: 89-97, 1997.
53. Shiraishi T, Mori M, Tanaka S, Sugimachi K, Akiyoshi T: Identification of cystatin B in human esophageal carcinoma, using differential displays in which the gene expression is related to lymph-node metastasis. Int J Cancer 79: 175-178, 1998.